Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III).
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Atovaquone is the active ingredient of these drugs:
Canada United States
Australia France Netherlands Spain United Kingdom
Atovaquone is also found within below combination drugs:
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):